AlphAIalphai — Financial news for AI agents
fool.comAUG 193 min read$KURA

Kura Oncology (KURA) Q2 2026 Earnings Call Transcript

Kura Oncology (KURA) reported Q2 2026 earnings, with KOMZIFTI net product revenue up 57% QoQ to $9.1M. New patient starts increased 35% to 115, capturing majority market share in a specific leukemia segment. Total prescriptions rose 59% to 250. Cash decreased to $519M from $667.2M. Collaboration revenue guidance set at $45M-$55M for 2026. Net loss was $68.3M, up from $66.1M YoY. Clinical data showed strong results for ziftomenib and darlifarnib. Management expects pivotal trial results in 2028.

Original reporting
fool.com
Published Aug 19, 2026, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Kura Oncology (KURA) Q2 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$KURANeutralHigh
01

Why it matters

The earnings beat on product revenue and strong cash reserves may support short‑term buying, while ongoing losses and trial timelines keep volatility high.

02

Market read

Earnings release provides fresh material for traders; impacts KURA and related menin inhibitor peers.

03

What to watch

Potential delays in pivotal trial readouts and reliance on Kyowa Kirin payments.

Relevance 8/10Novelty 8/10Timing: post‑earnings release

Background

Kura Oncology reported its Q2 2026 financial and operational metrics, highlighting product uptake and cash position.

Company-level read

Ticker impact

$KURANeutralHigh confidence
Context

Q2 2026 earnings call disclosed net product revenue of $9.1M, 57% QoQ growth, cash $519M and guidance for collaboration revenue $45-55M.

Expected impact

Potential modest price appreciation if guidance beats expectations; downside risk if cash burn concerns dominate.

Evidence & confidence

First disclosure of quarterly results provides fresh data; investors will reprice based on revenue beat and cash runway.

Market effects

Sector

Positive signal for menin inhibitor space and AML therapeutics.

Regional

U.S. biotech sector may see modest lift.

Global

Limited to specialty oncology investors.

Counterpoint

What could challenge this read

Cash burn and net loss could pressure the stock despite revenue growth.

Key entities

  • partner
    Kyowa Kirin

    Collaboration partner providing $180M anticipated payments.

Read at source← All news

Related articles

AUG 12
$KURAMed

Kura Oncology, Inc. (KURA): Results of Operations and Financial Condition

Kura Oncology, Inc. (KURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 kura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kura Oncology Reports SECOND Quarter 2026 Financial Results – KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q – – KOMZIFTI ® achi

SEC EDGAR 8-K6 min
MAY 29
$KURAMedAI 9/10

Kura Oncology Touts KOMZIFTI Launch Momentum, $3B Frontline AML Opportunity

Kura Oncology (NASDAQ:KURA) said at TD Cowen’s Oncology Innovation Summit it is building momentum for its newly approved AML therapy KOMZIFTI (ziftomenib) in relapsed/refractory NPM1-mutant AML, citing 85 new patient starts and 157 prescriptions in Q1 and $5.8M revenue. Executives also highlighted darlifarnib+adagrasib solid-tumor response data and updated KOMET-007 results ahead of ASCO and EHA.

dailypolitical.com7 min
AUG 24
$PMIMed

Biotech Gainers: PMI Revenue Growth, SDOT Earnings Surge, CAPR FDA Update, GRI Data Drive Gains

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

rttnews.com3 min
AUG 24
$GRRRMed

Gorilla Technology Group Q2 Earnings Call Highlights

Gorilla Technology Group reported $179.4M in cash at June-end, with $120M in debt. It expects Q3 revenue of $48M-$50M, Q4 above $60M, and $200M+ for 2026. 2027 targets are $450M-$500M. GPU-as-a-service projects may achieve 75%+ gross margins. The company raised its revenue outlook and plans to use project financing for deployments.

yahoo.com2 min
AUG 24
$SOHUMed

3 Low-P/E Stocks That Look Cheap as the S&P 500 Trades Near Record Highs

Sohu.com (SOHU), Onity Group (ONIT), and TriMas (TRS) trade at low P/E ratios (1.6x, 2.3x, 1.6x respectively) despite showing signs of business strength. SOHU reported 7% YOY revenue growth and improved profitability. ONIT saw 24% YOY revenue growth and 64% origination growth but faced servicing headwinds. TRS showed 1.6% YOY sales growth and 29% operating profit increase, with raised earnings guidance.

yahoo.com3 min
AUG 24
$NCTYHighAI 8/10

The9 Ltd (NCTY) (Q2 2026) Earnings Call Highlights: Record Net Income and 9Bit Token Surge

The9 Ltd (NCTY) reported Q2 2026 net income of $32M, a 39% increase, driven by 9Bit token valuation. The9Bit platform has 8M users, 110K games, and 41 brand partners. Expansion into US/Europe faces competition. Concerns include token volatility, leadership questions, and reliance on fair value recognition. The9 expects revenue growth from in-game purchases. MYB's Nasdaq listing, with The9 holding 15-16%, is imminent, valued at $7.7B.

yahoo.com2 min